RAPT Therapeutics Reports Improved Q1 2025 Results

Rapt Therapeutics Inc ( (RAPT) ) has released its Q1 earnings. Here is a breakdown of the information Rapt Therapeutics Inc presented to its investors.

RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in immunology-based therapies for inflammatory and immunological diseases. In its first quarter of 2025 financial report, RAPT Therapeutics highlighted a significant reduction in net loss, reporting $17.2 million compared to $30.5 million in the same period last year. The company attributes this improvement to decreased research and development expenses, particularly in the development of zelnecirnon and tivumecirnon, while increasing investment in RPT904 and early-stage programs. General and administrative expenses also saw a slight decrease, contributing to the overall financial performance. As of March 31, 2025, RAPT Therapeutics reported cash and cash equivalents and marketable securities totaling $179.3 million, reflecting a strong financial position to support ongoing and future projects. Looking ahead, the company remains optimistic about the potential of RPT904, with plans to initiate a Phase 2b trial in the second half of 2025, and anticipates further data from its partnership with Jemincare to guide its development strategy in treating chronic spontaneous urticaria.